SCHEMBL29059671

SCHEMBL29059671

COc1cc(N)ccc1N1CCC(CN2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.51
HTR4 Q13639 3/20 0.51
ALDH1A1 P00352 2/20 0.46
BACE1 P56817 1/20 0.44
CNR1 P21554 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NR1H2 P55055 1/20 0.43
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
GPR119 Q8TDV5 3/20 0.41
TGFBR1 P36897 1/20 0.41
TP53 P04637 1/20 0.41
STS P08842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21786071 0.87 CNR1 (0.44) ALDH1A1BACE1CNR1NPC1MAPT
SCHEMBL6807385 0.86 NR1H2 (0.52) ALDH1A1BACE1NPC1MAPTMAPK1
SCHEMBL30890229 0.86 NR1H2 (0.52) ALDH1A1BACE1NPC1MAPTMAPK1
SCHEMBL10036434 0.85 GPR119 (0.57) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL20046621 0.85 GPR119 (0.56) ALDH1A1CNR1NPC1MAPTMAPK1
SCHEMBL25259555 0.85 HTR4 (0.48) ACHEHTR4ALDH1A1MAPT
SCHEMBL25194818 0.85 KDM4E (0.46) ALDH1A1BACE1NPC1MAPTMAPK1
SCHEMBL25871541 0.83 GPR119 (0.47) ALDH1A1BACE1CNR1MAPTGPR119
SCHEMBL27162423 0.83 GPR119 (0.46) ALDH1A1BACE1CNR1L3MBTL1NR1H2
SCHEMBL30981434 0.82 GPR119 (0.57) ALDH1A1CNR1MAPTGPR119TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H BIOTECH INC. (KR) 2023-10-12 US disclosed
CN-116490184-A Compounds for inhibiting EGFR mutant cancers and pharmaceutical uses thereof J2H生物科技有限公司 2023-07-25 CN disclosed
EP-4212522-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H Biotech Inc. (KR) 2023-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF EGFR, KRAS, ERBB2 ACHE 4341/4885HTR4 4618/4885ALDH1A1 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.